Profil
Tom Woiwode has held positions as Chairman at iECURE, Inc. and Director at Belharra Therapeutics, Inc.
Postes actifs de Tom Woiwode
| Sociétés | Poste | Début |
|---|---|---|
IEcure, Inc.
 IEcure, Inc. BiotechnologyHealth Technology iECURE, Inc. is a gene editing company that focuses on developing therapies for liver disorders with significant unmet need. The company is based in Plymouth Meeting, PA, and the CEO of the company is Joseph Truitt. The company's approach involves mutation-agnostic in vivo gene insertion or knock-in editing, which has the potential to replace and restore the function of a dysfunctional gene, regardless of mutation. iECURE collaborates with the University of Pennsylvania's Gene Therapy Program to utilize their translational expertise and infrastructure. The company's management team has extensive experience in executing orphan drug and gene therapy clinical trials and successfully commercializing multiple products. iECURE's programs are currently focused on developing in vivo gene insertion therapies for the treatment of rare pediatric liver diseases. | Président | - |
Belharra Therapeutics, Inc.
 Belharra Therapeutics, Inc. Medical/Nursing ServicesHealth Services Belharra Therapeutics, Inc. is a drug discovery company that utilizes a unique photoaffinity-based chemoproteomics platform to identify novel small molecule drug candidates for previously difficult-to-treat diseases and conditions. The company is based in San Diego, CA, with its primary lab and offices located in the area. Belharra's proprietary discovery engine allows for the identification of small molecule starting points for drug development on any protein, in any conformational state, and in any cell type. The company was founded in 2021 by John Teijaro, Christopher G. Parker, Stuart L. Schreiber, and Benjamin F. Cravatt, and has since been led by CEO Jeffrey Jonker. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
IEcure, Inc.
IEcure, Inc. BiotechnologyHealth Technology iECURE, Inc. is a gene editing company that focuses on developing therapies for liver disorders with significant unmet need. The company is based in Plymouth Meeting, PA, and the CEO of the company is Joseph Truitt. The company's approach involves mutation-agnostic in vivo gene insertion or knock-in editing, which has the potential to replace and restore the function of a dysfunctional gene, regardless of mutation. iECURE collaborates with the University of Pennsylvania's Gene Therapy Program to utilize their translational expertise and infrastructure. The company's management team has extensive experience in executing orphan drug and gene therapy clinical trials and successfully commercializing multiple products. iECURE's programs are currently focused on developing in vivo gene insertion therapies for the treatment of rare pediatric liver diseases. | Health Technology |
Belharra Therapeutics, Inc.
Belharra Therapeutics, Inc. Medical/Nursing ServicesHealth Services Belharra Therapeutics, Inc. is a drug discovery company that utilizes a unique photoaffinity-based chemoproteomics platform to identify novel small molecule drug candidates for previously difficult-to-treat diseases and conditions. The company is based in San Diego, CA, with its primary lab and offices located in the area. Belharra's proprietary discovery engine allows for the identification of small molecule starting points for drug development on any protein, in any conformational state, and in any cell type. The company was founded in 2021 by John Teijaro, Christopher G. Parker, Stuart L. Schreiber, and Benjamin F. Cravatt, and has since been led by CEO Jeffrey Jonker. | Health Services |
